dc.contributor | Torres de Galvis, Yolanda | |
dc.creator | Pachón Espinosa, María Julieta | |
dc.creator | Rivera Jimenez, Claudia Marcela | |
dc.date.accessioned | 2016-10-12T16:30:59Z | |
dc.date.available | 2016-10-12T16:30:59Z | |
dc.date.created | 2016-10-12T16:30:59Z | |
dc.date.issued | 2016 | |
dc.identifier | http://repository.urosario.edu.co/handle/10336/12398 | |
dc.identifier | https://doi.org/10.48713/10336_12398 | |
dc.description.abstract | Introduction: The average time of maximum effect of rapid insulin in postprandial glycemia using regular insulin has been considered for years of 120 minutes. In patients with Diabetes Mellitus type 1 and 2 using analogue insulin, the time and associated factors to be applied in self-monitoring have not been reported yet. The objective of this study was to calculate the time and factors related to the maximal effect of insulin in postprandial glycemia. Methods: A retrospective longitudinal study was developed from a review of medical history of 80 patients. Descriptive and bivariate analyses were performed with demographic and clinical variables of the population. Results: The average time of peak insulin in patients with DM1 was 78.4 (SD ± 16,512) and DM2 75.01 (SD ± 12.02) minutes. 75% of the population with DM1 and 54.2% in DM2 were female, the average age of DM1 was 42.38 years and DM2 68 years, as to the categorization of BMI 50% of the population in DM1 and 37.5% in DM2 were within the range of obesity. A relationship with respect to the type of food "breakfast-dinner" vs. the average time of maximal effect of insulin calculated for both groups (p = 0.010) was found. Conclusion: The average time of maximal effect of insulin calculated was lower than reported in the clinical literature of 120 minutes. The type of main meal showed a relationship with the average time of maximum effect in both groups. | |
dc.language | spa | |
dc.publisher | Universidad del Rosario | |
dc.publisher | Maestría en Epidemiología | |
dc.publisher | Facultad de medicina | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights | Abierto (Texto completo) | |
dc.rights | Atribución-NoComercial-SinDerivadas 2.5 Colombia | |
dc.rights | EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma.
PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe.
EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización.
--------------------------------------
POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos. | |
dc.source | International Diabetes Federation: DF Diabetes Atlas.7 ed.International Diabetes Federation, 2015. Available from: URL: http://www.diabetesatlas.org | |
dc.source | Aschner P. Seminarios de diabetes: Epidemiología de la diabetes en Colombia. Avances en Diabetología 2010 Apr 1;26:95–100. | |
dc.source | Vashist SK. Continuous Glucose Monitoring Systems: A Review. Diagnostics 2013 Dec 3;(4): 385–412. | |
dc.source | Keenan DB, Cartaya R, Mastrototaro JJ. Accuracy of a New Real-Time Continuous Glucose Monitoring Algorithm. J Diabetes Sci Technol. 2010 Jan 1;4(1):111-8. | |
dc.source | Organización Panamericana de la Salud. Guía ALAD de diagnóstico, control y tratamiento de la Diabetes Mellitus tipo 2. Rev ALAD 2008. | |
dc.source | Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? . Diabetes 2005 Jan; 54(1): 1-7. | |
dc.source | Pérez A, Berenguer M. Algunas consideraciones sobre la diabetes mellitus y su control en el nivel primario de salud. MEDISAN 2015 Mar;19(3):374–89. | |
dc.source | Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for development of long-term complications: the perspective of the DCCT. Diabetes 1996;45:1289–98. | |
dc.source | Esteves MC, Gonçalves AM, Caldeira JL. Advanced glycosylation in diabetes mellitus. Occurrence of late complications. Acta Med Port 2001 Jul 1;14(4):409–12. | |
dc.source | Quirós C, Patrascioiu I, Giménez M, Vinagre I, Vidal M, Jansà M, Conget I. Assessment of use of specific features of subcutaneous insulin infusion systems and their relationship to metabolic control in patients with type 1 diabetes. Endocrinol Nutr 2014 Jun-Jul;61(6):318-22. | |
dc.source | Rivera AE, Sanchez J, Padilla A, Mendoza M, Tovar J. Diabetes Mellitus insulino dependiente: Efectos Amanecer y Somgyi en la variación de glucemia. Rev Mex Patol Clin 2003 Oct-Dec; 50 (4) 190-8 | |
dc.source | Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years. Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25(3): 593–8. | |
dc.source | Lagarde WH, Barrows FP, Davenport ML, Kang M, Guess HA, Calikoglu AS. Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind, randomized, controlled trial. Pediatr Diabetes 2006 Jun;7(3):159–64. | |
dc.source | Sachedina N and Pickup JC. Performance assesment of the MedtronicMiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects. Diabetic Medicine 2003.20: 1012-15 | |
dc.source | Pickup J, Martin M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002 Mar 23; 324: 705–8. | |
dc.source | Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med 2001 Oct 22; 161 (19): 2293–2300. | |
dc.source | .Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, et al. Design and Methods of a Randomized Trial of Continuous Glucose Monitoring in Persons With Type 1 Diabetes With Impaired Glycemic Control Treated With Multiple Daily Insulin Injections (GOLD Study). J Diabetes Sci Technol 2016 May 3;10(3):754-61 | |
dc.source | Poolsup N, Suksomboon N, Kyaw AM. Systematic review and metaanalysis of the effectiveness of continuous glucose monitoring (CGM) on glucose control in diabetes. Diabetol Metab Syndr 2013 Jul 23;5:39. | |
dc.source | Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol 2010 Dec;47 Suppl 1:77- 81. | |
dc.source | Currie CJ, Poole CD, Papo NL. An overview and commentary on retrospective, continuous glucose monitoring for the optimisation of care for people with diabetes. Curr Med Res Opin 2009 Oct;25(10):2389-40. | |
dc.source | Vigersky RA. The Benefits, Limitations, and Cost-Effectiveness of Advanced Technologies in the Management of Patients With Diabetes Mellitus. J Diabetes Sci Technol 2015 Mar;9(2):320-30. | |
dc.source | Chetty VT, Almulla A, Odueyungbo A, Thabane L. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1C) levels in Type 1 diabetic patients: A systematic review. Diabetes Res Clin Pract 2008 Jul;81(1):79-87. | |
dc.source | Evans JM, Newton RW, Ruta DA, MacDonald TM, Morris AD. Socioeconomic status, obesity and prevalence of type 1 and type 2 diabetes mellitus. Diabet Med 2000 Jun;17(6):478-80. | |
dc.source | Boyle JP, Engelgau MM, Thompson TJ, Goldschmid MG, Beckles GL, Timberlake DS, et al. Estimating prevalence of type 1 and type 2 diabetes in a population of African Americans with diabetes mellitus. Am J Epidemiol 1999 Jan 1;149(1):55–63. | |
dc.source | World Health Organization. Diet, nutrition and the prevention of chronic diseases: report of a joint WHO/FAO Expert Consultation. Geneva, Switzerland: World Health Organization 2003;54-71. | |
dc.source | Jin SM, Kim TH, Bae JC, Hur KY, Lee MS, Lee MK, et al. Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: An analysis of 480 subjects. Diabetes Res Clin Pract 2014 May;104(2):266-72. | |
dc.source | instname:Universidad del Rosario | |
dc.source | reponame:Repositorio Institucional EdocUR | |
dc.subject | Análogos de insulina | |
dc.subject | Comida | |
dc.subject | Sistema de Monitoreo continuo | |
dc.subject | Tiempo pico | |
dc.title | Tiempo promedio del efecto máximo de la insulina análoga en la glucemia postprandial y factores relacionados | |
dc.type | masterThesis | |